CBS62logoNEW2013_blue_final_header_White wwj950-sm2011b 971-ticket-35smb 35h_CBSSportsRad_Detroit

Cholesterol Drug Candidate

Esperion Therapeutics

Esperion Therapeutics Presents Promising Test Results On Cholesterol Drug

The pharma startup Esperion Therapeutics Inc. Monday announced full results of a Phase 2 clincal study of its lead drug candidate, called ETC-1002. The drug is intended to reduce high cholesterol levels in patients with a history of intolerance to today’s cholesterol-lowering statin drugs.

WWJ Newsradio 950–11/18/2013

Esperion Gets Positive Results From New Study Of Cholesterol Drug

Esperion Therapeutics Inc. Friday announced “positive” results from a Phase 2a clinical study of its product candidate ETC-1002 in patients with high cholesterol and a history of bad reactions to existing statin drugs.

WWJ Newsradio 950–06/09/2013

Follow

Get every new post delivered to your Inbox.

Join 1,933 other followers